Novartis ends mid-stage Fabhalta study in lupus, insists no efficacy or safety issues

Phase 2negativeFabhaltaNeutral

AI Analysis

Summary

Novartis terminated a mid-stage study of Fabhalta in lupus, saying the decision was not driven by efficacy or safety concerns. Fabhalta development continues in other indications, with late-stage readouts in atypical hemolytic uremic syndrome expected later this year and generalized myasthenia gravis next year.

Clinical Trial Data

Phase

Phase 2

Outcome Details

Novartis ended a mid-stage Fabhalta study in lupus, stating the decision was not due to efficacy or safety issues.

Importance:4/10

Sentiment:

-0.20

Fabhaltalupusstudy discontinuationPhase 2aHUSgeneralized myasthenia gravispipeline

Related Companies

$NVS

Read the original article

Published by BioSpace on October 19, 2026 1:17 PM

Read Original